Open Access

Clinical relevance of circulating cell-free microRNAs in ovarian cancer

  • Koji Nakamura1,
  • Kenjiro Sawada1Email author,
  • Akihiko Yoshimura1,
  • Yasuto Kinose1,
  • Erika Nakatsuka1 and
  • Tadashi Kimura1
Molecular Cancer201615:48

https://doi.org/10.1186/s12943-016-0536-0

Received: 7 February 2016

Accepted: 16 June 2016

Published: 24 June 2016

Abstract

Ovarian cancer is the leading cause of death among gynecologic malignancies. Since ovarian cancer develops asymptomatically, it is often diagnosed at an advanced and incurable stage. Despite many years of research, there is still a lack of reliable diagnostic markers and methods for early detection and screening. Recently, it was discovered that cell-free microRNAs (miRNAs) circulate in the body fluids of healthy and diseased patients, suggesting that they may serve as a novel diagnostic marker. This review summarizes the current knowledge regarding the potential clinical relevance of circulating cell-free miRNA for ovarian cancer diagnosis, prognosis, and therapeutics. Despite the high levels of ribonucleases in many types of body fluids, most of the circulating miRNAs are packaged in microvesicles, exosomes, or apoptotic bodies, are binding to RNA-binding protein such as argonaute 2 or lipoprotein complexes, and are thus highly stable. Cell-free miRNA signatures are known to be parallel to those from the originating tumor cells, indicating that circulating miRNA profiles accurately reflect the tumor profiles. Since it is well established that the dysregulation of miRNAs is involved in the tumorigenesis of ovarian cancer, cell-free miRNAs circulating in body fluids such as serum, plasma, whole blood, and urine may reflect not only the existence of ovarian cancer but also tumor histology, stage, and prognoses of the patients. Several groups have successfully demonstrated that serum or plasma miRNAs are able to discriminate patients with ovarian cancer patients from healthy controls, suggesting that the addition of these miRNAs to current testing regimens may improve diagnosis accuracies for ovarian cancer. Furthermore, recent studies have revealed that changes in levels of cell-free circulating miRNAs are associated with the condition of cancer patients. Discrepancies between the results across studies due to the lack of an established endogenous miRNA control to normalize for circulating miRNA levels, as well as differing extraction and quantification methods, are the pitfalls to be resolved before clinical application. There is still a long way, however, before this can be achieved, and further evidence would make it possible to apply circulating cell-free miRNAs not only as biomarkers but also as potential therapeutic targets for ovarian cancer in the future.

Keywords

Circulating miRNA Ovarian cancer Serum Plasma Early detection

Background

Ovarian cancer is the leading cause of gynecological cancer-associated deaths in developed countries. In the United States, ovarian cancer is the fifth leading cause of cancer death in females, with an estimated incidence of 14,180 deaths in 2015 [1]. High-grade serous ovarian cancer (HGSOC) accounts for 70–80 % of ovarian cancer deaths. While this disease is termed an ovarian cancer, a wide range of studies have suggested that secretory epithelial cells of the distal fallopian tube are the likely progenitors of a substantial proportion of HGSOCs, although some HGSOCs arise without fallopian tube [2]. While the survival rates of patients diagnosed with early stage ovarian cancer are high, most cases are diagnosed at a late stage with peritoneal dissemination. If diagnosed at an early stage, the 5-year survival rate exceeds 90 %. However, in patients with stage III or IV ovarian cancer, despite comprehensive treatments by aggressive cytoreductive surgery and chemotherapy with platinum- and taxane-based drugs, the 5-year survival rate remains at a dismal 30 % [1]. This high mortality rate of ovarian cancer is associated with the difficulties of early detection, because it is usually asymptomatic until late stage. Efficient early detection procedures have yet to be established. Although pelvic examination, transvaginal ultrasonography, and serum carbohydrate antigen 125 (CA125) are usually performed as routine diagnostic procedures for ovarian cancer, their diagnostic values are limited due to lack of the sensitivity and specificity [3]. For example, CA125 is only elevated in 50–60 % patients with stage I and II ovarian cancer [4]. In the retrospective study with 751 females, the sensitivity of CA125 for ovarian cancer at all stages was 88.6 %, but with a specificity of only 72.0 % [4]. In the recent study with 118 patients with ovarian cancer, 84 with benign disease, and 61 healthy females, the sensitivity and specificity of CA125 were 77.4 and 70.8 %, respectively [5]. Therefore, development of novel approaches to effectively detect ovarian cancer at an early, curable stage is urgently required. Another cause of this high mortality rate is the resistance to chemotherapy, especially in recurrent cases. Although ovarian cancer is highly responsive to the initial treatment by platinum- and taxane-based chemotherapies, subsequent relapses and repeated treatments using these cytotoxic chemotherapies eventually result in acquired resistance to the treatments. Therefore, most patients who experience cancer relapse eventually succumb to the disease [6]. In the last decade, a variety of targeted therapies have been developed to target the cancer-specific genes and proteins or the tumor microenvironment that contributes to cancer growth and maintenance. Among the new drugs studied for ovarian cancer, bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has shown promising activities in combination with standard chemotherapies in large Phase III trials [7, 8]. However, no significant benefits with respect to overall survival have been reported so far. Poly ADP ribose polymerase (PARP) inhibitors, which lead to formation of extensive double-stranded DNA breaks that cannot be accurately repaired in tumors, have shown potential for improved survival. Olaparib, a potent oral PARP inhibitor, significantly improved progression-free survival in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer; however, interim analysis showed no overall survival benefit [9]. Therefore, definitive treatments that substantially extend overall patient survival have yet to be established [10]. This is partly due to the lack of methods to discriminate between patients who will or will not benefit from the specific molecular targeted treatments. Thus, identification of useful clinical biomarkers to predict possible resistance to each treatment and prognoses of cancer patients would greatly benefit the management of ovarian cancer treatment [11]. Accumulating evidence has revealed that microRNAs (miRNA or miR) are extensively involved in cancer progression and suppression by regulating thousands of cancer-associated genes [12]. miRNAs can stably exist not only in cytoplasm, but also in various types of body fluids. Circulating cell-free miRNAs have been shown to have the potential to enable earlier cancer diagnosis and to predict prognosis and response to therapy [13]. This review summarizes the cumulative efforts in the field of circulating miRNAs focusing on their potential as novel biomarkers in ovarian cancer.

miRNAs and ovarian cancer

miRNAs are endogenously expressed, single-stranded non-coding RNAs that are typically 19–25 nucleotides in length. They are initially generated as long primary miRNAs (pri-miRNAs) by RNA II polymerase-mediated transcription in the cell nucleus. The primary miRNAs are cleaved into approximately 70 nucleotide-long precursor miRNAs, which are subsequently transported into the cytoplasm and further cleaved into mature miRNAs [14]. miRNAs predominantly act as transcriptional repressors by binding the 3’ untranslated region of their target messenger RNAs. It is well established that miRNAs are key regulators of post-transcriptional gene expression [14, 15]. In mammals, miRNAs are estimated to control the activities of more than 50 % of all protein-coding genes [16] and have been shown to be involved in the regulation of almost all cellular processes [17]. Drosha and Dicer are essential enzymes for the biogenesis of miRNA. Drosha, an RNase III enzyme, cleaves the pri-miRNA and releases a hairpin-structured pre-miRNA in the nucleus. After the pre-miRNA is exported into the cytoplasm, Dicer, another RNase III enzyme, cleaves the pre-miRNA and releases the miRNA duplexes. In ovarian cancer patients, low Dicer expression is significantly correlated with advanced stage ovarian cancer, and low Drosha expression with suboptimal surgery [18], suggesting that impaired processing of miRNAs by Dicer and Drosha is involved in the tumorigenesis of ovarian cancer, and it leads to poor clinical outcomes [19]. Many studies have shown that dysregulation of miRNAs is involved in a variety of human diseases including ovarian cancer [19, 20]. The Cancer Genome Atlas (TCGA) project analyzed mRNA expression, miRNA expression, promoter methylation, and DNA copy number in a total of 489 HGSOCs and showed that ovarian cancers could be separated into 3 miRNA subtypes [21]. Among these, a robust integrated mesenchymal subtype was associated with poor survival, and eight key miRNAs (miR-25, miR-29c, miR-101, miR-128, miR-141, miR-182, miR-200a, and miR-506) were identified [22]. Mining the TCGA data, Miles et al. identified 17 miRNAs that were dysregulated in HGSOCs in comparison with normal ovary samples, including eight upregulated miRNAs (miR-183-3P, miR-15b-3p, miR-15b, miR-590-5p, miR-18a, miR-16, miR-96, and miR-18b) and nine downregulated miRNAs (miR-140-3p, miR-145-3p, miR-143-5p, miR-34b-5p, miR-145, miR-139-5p, miR-34c-3p, miR-133a, and miR-34c-5p) [23, 24]. Emerging evidence has revealed the role of microRNAs in ovarian cancer as oncogenes or tumor suppressor genes. For instance, Ohyagi-Hara et al. identified that miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression, which had previously been shown as a key molecule in peritoneal dissemination [25, 26]. Kinose et al. demonstrated that miR-199a-3p is downregulated in high-grade serous ovarian carcinomas, and the loss of miR-199a-3p is involved in ovarian carcinogenesis and peritoneal dissemination by causing the upregulation of c-Met, a receptor against hepatocyte growth factor [27]. Davidson et al. and Zhang et al. summarized the roles of miRNAs in ovarian cancer in their review papers [24, 28].

miRNAs in circulation

Since high levels of endogenous nucleases are present in body fluids, freely circulating RNAs were expected to be rapidly degraded. However, recent evidence has revealed that miRNAs are secreted from cells into circulation where they exist stably, and sometimes can be functionally transferred to recipient cells [29, 30]. Circulating miRNAs were first detected in the serum and plasma [31, 32] in 2008, and subsequently found in a variety of body fluids, such as saliva, urine, breast milk, and so on [3358] (Fig. 1). One of the first studies measuring miRNA levels in the serum was reported by Mitchell et al. [31], who found that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity. They could distinguish patients with prostate cancer from healthy subjects by measuring the serum levels of miR-141. In 2009, Park NJ, et al. reported that endogenous salivary miRNAs were degraded at much slow rates compared with exogenous miRNA, and that both miR-125a and miR-200a were present at significantly lower levels in the saliva of oral squamous cell carcinoma patients than in control subjects, indicating the presence of miRNA in saliva [46]. Currently, circulating miRNAs are known to be remarkably stable under harsh conditions, such as extreme pH values, high temperatures, and long-term storage [31, 32, 56]. Current studies have suggested that miRNAs are released from cells into circulation by using several packaging and transportation systems to avoid degradation (Fig. 2): (a) Active secretion: miRNAs are encapsulated in extracellular membrane vesicles such as exosomes (30–100 nm) or microvesicles (50–1000 nm) [29, 59]. They are also secreted via binding to miRNA-binding proteins, such as AGO2, or serum lipid carriers, such as HDL [60, 61]. (b) Passive leakage: miRNAs are involved in shedding vesicles, such as apoptotic bodies (−4000 nm), as a result of apoptotic death [62]. Previous studies have demonstrated that miRNA expression profiles are different depending on the physiological and pathological conditions [63]. In other words, some miRNAs are upregulated or downregulated specifically in certain cancer types. This stability and specificity make circulating miRNAs potential biomarkers of cancer diagnosis [13].
Fig. 1

miRNAs in various human body fluids. miRNAs can be detected in various human body fluids. Circulating miRNAs reported as potential non-invasive diagnostic markers for many types of cancers are shown. miRNAs which were reported to be upregulated in cancer patients compared to controls (healthy or benign) are shown in red, and those downregulated in cancer patients are shown in blue. In [39], miR-21 and miR-1225-5p were overexpressed in ascites from serosa-invasive gastric cancer patients compared with non-invasive gastric cancer patients. In breast milk, 3 most abundant miRNAs are listed in the figure. PCNSL: primary central nervous system lymphoma; NSCLC: non-small cell lung cancer

Fig. 2

Circulating miRNAs derived from ovarian cancer. Ovarian cancer-associated miRNAs are reported to be detected from blood (serum/plasma), urine, or ascites. MiRNAs in circulation display remarkable stability. They are encapsulated by membrane-enclosed vesicles such as exosomes and microvesicles, or bound to carrier protein or lipids such as Argonaute2 (Ago2) and HDL. miRNAs are protected by these miRNA-carriers from RNase in circulation [29, 5962]. HDL: high density lipoprotein

Methodologies for the collection and analysis of circulating miRNAs

The expression profile of circulating miRNAs is highly affected by the methodologies of sample preparation [60, 64]. How to prepare samples adequately depends on the types of body fluids. In ovarian cancer research, samples were generally collected from blood, ascites, or urine. Blood samples were firstly processed into serum or plasma in most studies. For urine analyses, morning whole-stream urine samples were collected [41]. Ascites was collected for routine diagnostic purposes during gynecological surgeries or abdominocentesises. Thereafter, they were centrifuged to avoid contamination of cell fraction and stored in −80 °C [41, 6580]. In exosomal miRNA research, exosomes were collected using an ultracentrifugation method or a commercial-based exosome isolation kit such as ExoQuick (SBI, Palo Alto, CA) [30, 50]. Thereafter, the extraction of RNA is usually performed by using commercially available techniques including phenol/guanidinium products, such as TRIzol (Life Technologies), and column-based extraction kits, such as mirVana (Life Technologies) and miRNeasy (QIAGEN).

In most studies, the extracted miRNAs are subjected to next-generation sequencing (NGS) or miRNA microarrays to obtain large-scale profiles of circulating miRNAs and determine candidate miRNAs for further quantification. Each method has certain advantages and limitations. NGS has a potential to identify novel miRNAs but is less cost-effective and less efficient compared with microarrays. Thereafter, the candidate miRNAs are generally subjected to further validation by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in larger cohorts. Establishment of endogenous controls for miRNA normalization remains the bottleneck for the reliable quantification of miRNAs. While RNU-6B, RNU-48, and miR-16 are commonly used as endogenous controls, no definitive control gene has been established [13, 81]. Recent studies have suggested more reliable endogenous controls for the quantification of circulating miRNAs [82, 83]. Chen et al. reported that a combination of let-7d, let-7 g and let-7i serves as an endogenous control of serum miRNAs and it is superior to the commonly used reference genes [82]. Kok et al. suggested normalization panels for the better quantification of circulating microRNAs by RT-qPCR [83]. Further studies with a large number of samples would be needed to determine a suitable reference for reliable normalization of circulating miRNAs.

Clinical relevance of cell-free miRNAs in ovarian cancer

Since 2008, numerous studies have demonstrated the clinical relevance of circulating miRNAs as diagnostic and prognostic biomarkers for a variety of cancer types, using blood plasma or serum. Cancer-associated circulating miRNA expression profiles were determined and have been shown to be related to tumor development, disease progression, and metastases. This section describes the potential roles of circulating miRNAs as novel biomarkers in regard to diagnosis and prognosis in ovarian cancer.
  1. 1.

    Diagnostic potential of circulating miRNAs in ovarian cancer

    Approximately 20 studies have been published on the diagnostic potential of circulating miRNAs in ovarian cancer. Taylor et al. first reported that eight exosomal miRNAs (miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, and miR-214) from sera were elevated in ovarian cancer patients compared to benign controls, which had been reported to be overexpressed in ovarian cancer tissues. These miRNAs were overexpressed even in patients with early stages of ovarian cancer. The miRNA signatures from exosomes were parallel to those from the originating tumor cells, indicating that circulating miRNA profiles accurately reflect the tumor profiles [50]. Following this study, various reports have demonstrated the diagnostic potential of circulating miRNAs in body fluids such as serum, plasma, whole blood, and urine [41, 6580] as summarized in Table 1. Hauser et al. investigated the miRNA expression pattern in relapsed ovarian cancer patients from whole blood samples containing cellular fraction by miRNA array. They reported that miR-30c-1-3p was upregulated, and miR-342-3p, miR-181a-3p, and miR-450b-5p were downregulated in patients with relapsed ovarian cancer when compared to healthy controls [66]. Kan et al. reported that the expression levels of four serum miRNAs including the miR-200 family (miR-182, miR-200a, −200b, and -200c) were significantly elevated in serous ovarian cancer patients compared with healthy volunteers. They identified a multivariate model combining miR-200b and miR-200c that has good predictive power to discriminate patients with serous ovarian cancer and healthy controls (AUC = 0.784), and this model may have utility as potential biomarkers of serous ovarian cancer [67]. Chung et al. analyzed an miRNA array using RNAs isolated from serum, tissue, and ascites from serous ovarian cancer patients and a healthy control, and identified five miRNAs (miR-132, miR-26a, let-7b, miR-145, and miR-143) as the most significantly downregulated miRNAs in the sera of ovarian cancer patients with respect to those of the control [68]. Zheng et al. evaluated plasma samples of 360 epithelial ovarian cancer patients and 200 healthy controls and found higher expression of plasma miR-205 and lower expression of let-7f in the ovarian cancer patients. Combination of miR-205 and let-7f together provided high diagnostic accuracy for epithelial ovarian cancer (AUC = 0.831 (95 % CI, 0.772 to 0.880; sensitivity = 62.4 %, specificity = 92.9 %), particularly in patients with stage I disease, indicating that these two miRNA signatures could be used as biomarkers of ovarian cancer detection, particularly for stage I disease [69]. Suryawanshi et al. focused on endometriosis-associated ovarian cancer (EAOC) (endometrioid adenocarcinoma or clear cell carcinoma) and revealed three plasma miRNAs, miR-16, miR-191, and miR-195, all upregulated in endometriosis, that could differentiate between healthy and endometriosis cases with 88 % sensitivity and 60 % specificity. They further showed that a combination of miR-16, miR-21, and miR-191 could differentiate between healthy and EAOC with 86 % sensitivity and 85 % specificity and that miR-21, miR-191, and miR-1975 together could distinguish between EAOC and serous ovarian cancer with 86 % sensitivity and 79 % specificity [70]. Zuberi et al. reported that serum miR-200a is significantly upregulated in mucinous adenocarcinomas compared with other types of histology in 70 epithelial ovarian cancer patients and at the highest AUC value, the sensitivity and specificity of this miRNA relative expression were 80.6 and 73.5 %, respectively [79]. Meng et al. revealed that serum levels of mR-25 and miR-93 were downregulated, while those of miR-7 and miR-429 were upregulated in 180 epithelial ovarian cancer patients compared with 66 healthy women. These four miRNA signatures discriminated ovarian cancer patients from healthy women with a high sensitivity and specificity: 93 and 92 %, respectively [75]. Zhou et al. reported diagnostic value of urinary miRNAs in ovarian cancer. They identified significant upregulation of miR-30a-5p in the urine sample of ovarian cancer patients when compared to healthy controls. They also identified that miR-30a-5p was concentrated in exosomes from ovarian cancer cell culture supernatant and urine from ovarian cancer patients, supporting a pathway for miR-30a-5p excretion into the urine [41]. Kapetanakis et al. showed that plasma miR-200b was significantly more abundant in patients with ovarian cancer than in those with benign tumors. They suggested the potential role of miR-200b as a complementary biomarker of CA125, because there was no significant correlation between the distributions of these markers [80].
    Table 1

    Circulating miRNAs as potential diagnostic biomarkers of ovarian cancer

    Reference

    Elevated miRNA

    Decreased miRNA

    Source

    Tumor histology (n)

    FIGO stage (n)

    Control (n)

    Serous

    Others

    I-II

    III-IV

    HC

    Ben

    Bor

    [50], 2008

    miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR-214

     

    Serum (exosome)

    50

     

    20

    30

    10

    10

     

    [65], 2009

    miR-21, miR92, miR-93, miR-126,miR-29a

    miR-155, miR-127, miR-99b

    Serum

    17

    11

    10

    18

    15

      

    [66], 2010

    miR-30c-1

    miR-342-3p, miR-181a, miR-450-5p

    Whole blood

    21

    3

    Relapsed

     

    15

      

    [67], 2012

    miR-182, miR-200a, miR-200b, miR-200c

     

    Serum

    28

     

    1

    27

    28

      

    [68], 2013

     

    miR-132, miR-26a, let7-b, miR-145

    Serum

    18

     

    3

    14

    12

      

    [69], 2013

    miR-205

    let-7f

    Plasma

    179

    181

    133

    227

    200

      

    [70], 2013

    miR-16, miR-21, miR-191 (EAOC) miR-16, miR-191, miR-4284 (SOC)

     

    Plasma

    21

    14

    12

    23

    20

    33

     

    [71], 2013

    miR-21

     

    Serum

    68

    26

    32

    62

    40

      

    [72], 2013

    miR-221

     

    Serum

    70

    26

    32

    64

    35

      

    [73], 2014

    miR-191-5p, miR-206, miR-548a-3p, miR-320a, miR-574-3p, miR-590-5p, miR-34c-5p, miR-106b-5p

    miR-19a-3p, miR-30a-5p, miR-645, miR-150-5p

    Plasma

    18

    0

    6

    12

    24

      

    [74], 2014

    miR-1274a, miR-625-3p, miR-720

    miR-106b, miR-126, miR-150, miR-17, miR-20a, miR-92a

    Plasma

    42

     

    6

    36

    23

    36

     

    [75], 2015

    miR-7, miR-429

    miR-25,miR-93

    Serum

    120

    60

    32

    147

    66

      

    [41], 2015

    miR-30-5p

     

    Urine

    39

     

    16

    18

    30

    26

     

    [76], 2015

    miR-141, miR-200c

     

    Serum

    16

    58

    54

    20

    50

     

    19

    [77], 2015

     

    miR-145

    Serum

    18

    64

    31

    63

    135

      

    [78], 2015

     

    let-7i-5p, miR-122, miR-152, miR-25-3p

    Serum/plasma

    20

     

    6

    19

     

    25

     

    [79], 2015

    miR-200a, miR-200b, miR-200c

     

    Serum

    70

     

    33

    37

    70

      

    [78], 2015

    miR-200b

     

    Plasma

    51

     

    6

    45

    25

    25

     

    FIGO: International Federation of Gynecology and Obstetrics, EAOC; endometriosis associated ovarian carcinoma, SOC; serous ovarian carcinoma, HC; healthy control, Ben; Benign control, Bor; borderline tumor

     
  2. 2.

    Potential of circulating miRNAs in ovarian cancer as prognostic biomarkers

    Current management of ovarian cancer relies on clinicopathological factors including tumor histology and stage. Recent studies have revealed that changes in the levels of circulating miRNAs are associated with the prognosis of ovarian cancer patients [38, 69, 71, 72, 7477, 80], as summarized in Table 2. Zheng et al. demonstrated that lower plasma let-7f expression was significantly correlated with poor progression-free survival (PFS) in 360 ovarian cancer patients, particularly in stage III and IV cases. Cox regression analysis revealed that plasma let-7f was an independent prognostic indicator of ovarian cancer in PFS [69]. Zhao et al. investigated the serum level of miR-21 in a total of 94 epithelial ovarian cancer patients. They showed that increased serum miR-21 expression was associated with advanced FIGO stage, high tumor grade, and shortened overall survival (OS), and that a high level of serum miR-21 expression was an unfavorable prognostic factor independent of other clinicopathological factors [71]. Vaksman et al. studied miRNA expression in effusion-derived exosomes. Exosomes were collected from 66 malignant peritoneal and 20 pleural effusions obtained from a total of 86 ovarian cancer patients with advanced stages. They demonstrated that high levels of miR-21, miR-23b, and miR-29a were associated with poor PFS in univariate analyses. In addition, high expression of miR-21 was correlated with poor OS in Cox regression analysis [38]. Gao et al. investigated the diagnostic and prognostic potential of serum miR-200c and miR-141, which are members of the miR-200 family, in 74 ovarian cancer patients. Both miRNAs were significantly overexpressed in ovarian cancer patients compared to 50 healthy control. Patients with high miR-200c levels achieved a significantly higher 2-year survival rate, while the low miR-141 group showed a significantly higher survival rate [76].
    Table 2

    Circulating miRNAs as potential prognostic predictors of ovarian cancer

    Reference

    miRNAs associated with poor prognosis

    Endpoint

    Source

    Patients (n)

    Histology (n)

    FIGO stage (n)

     

    Increased miRNAs

    Decreased miRNAs

       

    Serous

    Others

    I-II

    III-IV

    [69], 2013

     

    let-7f

    PFS

    Plasma

    360

    179

    181

    133

    227

    [71], 2013

    miR-21

     

    OS

    Serum

    94

    68

    26

    32

    62

    [72], 2013

    miR-221

     

    OS

    Serum

    96

    70

    26

    32

    64

    [74], 2014

     

    miR-1290

    OS

    Plasma

    26

    26

    0

    6

    36

    [38], 2014

    miR-21,miR-23b, miR-29a (PFS), miR-21(OS)

     

    PFS/OS

    Effusion (exosome)

    86

    76

    10

    0

    86

    [75], 2015

    miR-429

     

    OS

    Serum

    180

    180

     

    32

    147

    [76], 2015

    miR-141

    miR-200c

    OS

    Serum

    74

    16

    58

    54

    20

    [77], 2015

     

    miR-145

    OS

    Serum

    82

    18

    64

    31

    53

    [80], 2015

    miR-200b

     

    PFS

    Plasma

    33

    33

     

    Unknown

     

    FIGO: International Federation of Obstetrics and Gynecology, PFS: progression free survival, OS: overall survival

     

Several research groups have studied the ability of miRNAs to predict the sensitivity to treatment. Kapetanakis et al. demonstrated the pre/post-treatment variations of plasma miR-200b in ovarian cancer as a potential prognostic predictor. Plasma samples were collected from a total of 33 ovarian cancer patients prior to and after primary treatment including surgery and chemotherapy. CA125 returned to normal plasma concentrations within the first month of treatment in almost all patients even in the cases with unresectable tumor, whereas there was a remarkable mix of variation in the concentrations of plasma miR-200b. The patients with a negative miR-200b variation had a longer PFS than those patients with a positive variation, and the risk of disease-progression was significantly higher in patients with a positive variation of miR-200b compared to those with a negative variation [80]. Benson et al. conducted a pilot study to identify plasma miRNAs that can predict outcomes of a specific chemotherapy regimen: carboplatin with decitabine, a hypomethylating agent. Plasma samples were collected from 14 recurrent platinum-resistant ovarian cancer patients prior to and at the end of the first cycle of treatment, and the changes in plasma miRNA concentrations were evaluated. Lower concentrations of circulating plasma miR-148b-5p were associated with worse PFS, suggesting its potential as a novel biomarker of therapeutic response [84].

Can circulating miRNA predict the response to novel cancer treatments?

While a variety of molecular targeted therapies (e.g. bevacizumab, olaparib, or cediranib (a pan-VEGFR inhibitor) [85] have been developed for ovarian cancer treatment and showed some improvements in progression-free survival of patients, no significant benefits with respect to overall survival have been reported so far [710, 85]. This is partly due to the lack of methods to discriminate between patients who will or will not benefit from these novel treatments. Since these therapies would be applied mainly for relapsed ovarian cancer patients and it would not be practically possible to obtain tumors in most relapsed cases, the identification of novel biomarkers from body fluids such as serum, plasma, whole blood, and urine would be indispensable especially to those patients. Thus, circulating cell free miRNAs in body fluids are to be good candidates and need to be extensively analyzed. At present, there have been no reports which showed the association between these novel drugs and circulating miRNAs in ovarian cancer; however, the recent study in metastatic colorectal cancers revealed that changes in circulating plasma miR-126 during treatment were predictive of tumor response to the first-line chemotherapy (XELOX; capecitabine and oxaliplatin) combined with bevacizumab [86]. While the responding patients had a significant decrease of circulating miR-126, this circulating miRNA modestly increased in non-responding patients. MiR-126 is known to have a high endothelial cell (EC) specificity and involved in EC proliferation, migration, survival, and in the regulation of blood vessel integrity [87, 88], indicating that the circulating level of this miRNA may reflect the response to bevacizumab. Such efforts would be taken in ovarian cancer treatment in the near future.

Can circulating miRNAs be therapeutic targets for cancer treatment?

He WA, et al. reported cancer-secreted microvesicles contain an elevated expression of miR-21 and induce myoblast apoptosis, which lead to cancer cachexia of patients via a Toll-like receptor 7 (TLR7) [89]. They provided insights into therapeutic avenues for cachexia, possibly by inhibiting microvesicles secretion, inhibiting fusion of microvesicles with muscle cells, or blocking the binding of miR-21 to TLR7/8. Ciravolo et al. reported that the exosomes released by the HER2-overexpressing breast cancer cell lines express a full-length HER2 molecule and that these exosomes bound to trastuzumab and inhibited its anticancer cell proliferative activity [90]. Based on this preclinical data, Aethlon Medical Inc. (CA, USA) has developed HER2osome™, as a therapeutic strategy to combat HER2 positive breast cancer through the capture of circulating HER2-positive exosomes [91]. Although promising results from these novel devices in the clinical settings have not been reported so far, such approaches to eliminate circulating microvesicles containing miRNAs have the potential to be a breakthrough in cancer therapy.

Conclusions

In recent years, emerging evidence has suggested that circulating miRNAs may hold great potential as promising biomarkers for early detection, prognosis, and sensitivity to chemotherapy of ovarian cancer. However, to date, most of the studies appear to be preliminary, because they simply identified altered levels of circulating miRNAs in ovarian cancer patients with relatively small cohort sizes. They lack direct comparison or in combination with conventional diagnostic procedures, such as CA125 and ultrasonography, particular for early stage diseases. In addition, the lack of standardized protocols including sample collection, RNA extraction, and the selection of suitable internal control makes it difficult to compare the results between studies reported. There have been inconsistent findings about circulating miRNAs from the same tumor reported by different studies. Nevertheless, circulating miRNAs have potential as novel non-invasive and highly useful biomarkers of ovarian cancer, as shown in various types of disease such as cardiovascular disease, diabetes mellitus, and cancer of other organs [92]. Further studies with standardized procedures and at larger scales are warranted to enhance the consideration of the clinical significance of circulating miRNAs in ovarian cancer. Recently several big projects focusing on circulating miRNAs as a biomarker have launched. For instance, NIH launched the Extracellular RNA Communication program to advance the field of extracellular miRNA research in 2013. The NIH Common Fund awarded approximately $130 million to 30 research projects to investigate the diagnostic and therapeutic potential of circulating miRNAs [93]. In Japan, a big project led by the New Energy and Industrial Technology Development Organization (NEDO), a national research agency, started in 2014. This project aims to enable the early detection of 13 types of cancers including ovarian cancer using circulating miRNAs from blood samples of 65,000 people [94]. These projects may be great milestones to establish miRNA-based ovarian cancer detection. In addition, several basic research studies have demonstrated that circulating miRNAs can be mediators of cell-to-cell communication during cancer progression [89, 95, 96]. There is still a long way, however, and further evidence would make it possible to use circulating miRNAs not only as biomarkers but also as potential therapeutic targets in the future.

Declarations

Acknowledgements

We thank Mami Morikawa for her secretarial assistance.

Funding

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (24592515, 26670725, and 26293360 to KS, and 24249080 to TK).

Authors’ contributions

KN wrote the initial draft and designed the outline of the article. KS designed the outline of the article, revised and expanded the manuscript. AY, YK, EN gave useful suggestions. TK supervised the manuscript. All authors have seen and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.View ArticlePubMedGoogle Scholar
  2. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast Jr RC, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;11:668–79.View ArticleGoogle Scholar
  3. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295–302.View ArticlePubMedGoogle Scholar
  4. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308–12.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One. 2012;7(9):e44960.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.View ArticlePubMedGoogle Scholar
  7. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.View ArticlePubMedGoogle Scholar
  8. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.View ArticlePubMedGoogle Scholar
  9. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.View ArticlePubMedGoogle Scholar
  10. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian Cancer. Lancet. 2014;384:1376–84.View ArticlePubMedGoogle Scholar
  11. Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, et al. MicroRNAs as prognostic markers in ovarian cancer. Mol Cell Endocrinol. 2014;390:73–84.View ArticlePubMedGoogle Scholar
  12. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314.View ArticlePubMedGoogle Scholar
  13. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11:145–56.View ArticlePubMedGoogle Scholar
  14. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376–85.View ArticlePubMedGoogle Scholar
  15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.View ArticlePubMedGoogle Scholar
  16. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.PubMedGoogle Scholar
  17. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67:129–39.View ArticlePubMedGoogle Scholar
  18. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359:2641–50.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Kinose Y, Sawada K, Nakamura K, Kimura T. The role of microRNAs in ovarian cancer. Biomed Res Int. 2014;2014:249393.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs. 2007;21:97–104.View ArticlePubMedGoogle Scholar
  21. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.View ArticleGoogle Scholar
  22. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:186–99.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes. 2012;5:164.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly KA, Calin GA, et al. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res. 2015;13:393–401.View ArticlePubMedGoogle Scholar
  25. Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression. Am J Pathol. 2013;182:1876–89.View ArticlePubMedGoogle Scholar
  26. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008;68:2329–39.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015;6:11342–56.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Davidson B, Tropé CG, Reich R. The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol. 2014;133:640–6.View ArticlePubMedGoogle Scholar
  29. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.View ArticlePubMedGoogle Scholar
  30. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285:17442–52.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.View ArticlePubMedGoogle Scholar
  33. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117:3140–6.View ArticlePubMedGoogle Scholar
  34. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013;8:e78115.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013;133:645–52.View ArticlePubMedGoogle Scholar
  36. Shin YM, Yun J, Lee OJ, Han HS, Lim SN, An JY, et al. Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion. Cancer Res Treat. 2014;46:178–85.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Ak G, Tomaszek SC, Kosari F, Metintas M, Jett JR, Metintas S, et al. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. 2015;2015:635748.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Vaksman O, Tropé C, Davidson B, Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35:2113–20.View ArticlePubMedGoogle Scholar
  39. Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro M, Hirakawa K, et al. Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer. PLoS One. 2015;10:e0130472.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Liu J, Sun H, Wang X, Yu Q, Li S, Yu X, et al. Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci. 2014;15:758–73.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015;33:2915–23.PubMedGoogle Scholar
  42. Zhou X, Zhang X, Yang Y, Li Z, Du L, Dong Z, et al. Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer. Med Oncol. 2014;31:197.View ArticlePubMedGoogle Scholar
  43. Zhang DZ, Lau KM, Chan ES, Wang G, Szeto CC, Wong K, et al. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One. 2014;9:e100793.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Erbes T, Hirschfeld M, Rücker G, Jaeger M, Boas J, Iborra S, et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer. 2015;15:193.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5:182–91.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15:5473–7.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One. 2013;8:e57502.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Xie Z, Yin X, Gong B, Nie W, Wu B, Zhang X, et al. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. Cancer Prev Res (Phila). 2015;8:165–73.View ArticleGoogle Scholar
  49. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733–41.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13–21.View ArticlePubMedGoogle Scholar
  51. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47:784–91.View ArticlePubMedGoogle Scholar
  52. Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61:187–93.View ArticlePubMedGoogle Scholar
  53. Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 2012;138:671–4.View ArticlePubMedGoogle Scholar
  54. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:2084–92.View ArticlePubMedGoogle Scholar
  55. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2015;136:152–61.View ArticlePubMedGoogle Scholar
  57. Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV, et al. Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res. 2015;3:12.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36:3035–42.View ArticlePubMedGoogle Scholar
  59. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107:1047–57.View ArticlePubMedGoogle Scholar
  60. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–8.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Vickers KC, Remaley AT. Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol. 2012;23:91–7.View ArticlePubMedGoogle Scholar
  62. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2:ra81.View ArticlePubMedGoogle Scholar
  63. Wittmann J, Jäck HM. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta. 1806;2010:200–7.Google Scholar
  64. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298–301.View ArticlePubMedPubMed CentralGoogle Scholar
  65. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112:55–9.View ArticlePubMedGoogle Scholar
  66. Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010;103:693–700.View ArticlePubMedPubMed CentralGoogle Scholar
  67. Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 2012;12:627.View ArticlePubMedPubMed CentralGoogle Scholar
  68. Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int J Gynecol Cancer. 2013;23:673–9.View ArticlePubMedGoogle Scholar
  69. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One. 2013;8:e77853.View ArticlePubMedPubMed CentralGoogle Scholar
  70. Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2013;19:1213–24.View ArticlePubMedPubMed CentralGoogle Scholar
  71. Xu YZ, Xi QH, Ge WL, Zhang XQ. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14:1057–60.View ArticlePubMedGoogle Scholar
  72. Hong F, Li Y, Xu Y, Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res. 2013;41:64–71.View ArticlePubMedGoogle Scholar
  73. Ayaz L, Çayan F, Balci Ş, Görür A, Akbayir S, Yıldırım Yaroğlu H, et al. Circulating microRNA expression profiles in ovarian cancer. J Obstet Gynaecol. 2014;34:620–4.View ArticlePubMedGoogle Scholar
  74. Shapira I, Oswald M, Lovecchio J, Khalili H, Menzin A, Whyte J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 2014;110:976–83.View ArticlePubMedGoogle Scholar
  75. Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer. 2015;113:1358–66.View ArticlePubMedGoogle Scholar
  76. Gao YC, Wu J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour Biol. 2015;36:4843–50.View ArticlePubMedGoogle Scholar
  77. Liang H, Jiang Z, Xie G, Lu Y. Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour Biol. 2015;36:5305–13.View ArticlePubMedGoogle Scholar
  78. Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett. 2015;356:628–36.View ArticlePubMedGoogle Scholar
  79. Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, et al. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol. 2015;17:779–87.View ArticlePubMedGoogle Scholar
  80. Kapetanakis NI, Uzan C, Jimenez-Pailhes AS, Gouy S, Bentivegna E, Morice P, et al. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA125 and potential for prediction of progression-free survival. Oncotarget. 2015;6:36815–24.PubMedPubMed CentralGoogle Scholar
  81. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.View ArticlePubMedGoogle Scholar
  82. Chen X, Liang H, Guan D, Wang C, Hu X, Cui LA, et al. Combination of let-7d, let-7 g and let-7i serves as a stable reference for normalization of serum microRNAs. PLoS One. 2013;8:e79652.View ArticlePubMedPubMed CentralGoogle Scholar
  83. Kok MG, Halliani A, Moerland PD, Meijers JC, Creemers EE, Pinto-Sietsma SJ. Normalization panels for the reliable quantification of circulating microRNAs by RT-qPCR. FASEB J. 2015;29:3853–62.View ArticlePubMedGoogle Scholar
  84. Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. PLoS One. 2015;10:e0141279.View ArticlePubMedPubMed CentralGoogle Scholar
  85. Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–74.View ArticlePubMedGoogle Scholar
  86. Hansen TF, Carlsen AL, Heegaard NH, Sørensen FB, Jakobsen A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015;112:624–9.View ArticlePubMedPubMed CentralGoogle Scholar
  87. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261–71.View ArticlePubMedPubMed CentralGoogle Scholar
  88. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272–84.View ArticlePubMedPubMed CentralGoogle Scholar
  89. He WA, Calore F, Londhe P, Canella A, Guttridge DC, Croce CM. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014;111:4525–9.View ArticlePubMedPubMed CentralGoogle Scholar
  90. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol. 2012;227:658–67.View ArticlePubMedGoogle Scholar
  91. http://www.aethlonmedical.investorroom.com/index.php?s=43&item=94. Aethlon Medical Inc, 2011.
  92. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9:850–9.View ArticlePubMedGoogle Scholar
  93. http://www.ncats.nih.gov/exrna. NIH, 2016. Accessed 11 Jun 2016.
  94. http://www.nedo.go.jp/engligh/index.html. Accessed 16 Dec 2015.
  95. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–15.View ArticlePubMedPubMed CentralGoogle Scholar
  96. Le MT, Hamar P, Guo C, Basar E, Perdigão-Henriques R, Balaj L, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014;124:5109–28.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Nakamura et al. 2016